Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
|Articles|December 26, 2017
Supplements and Featured Publications
- Exclusive Coverage of the NEUROSCIENCE EDUCATION INSTITUTE (NEI) 2017 CONGRESS
Exclusive Coverage of the NEUROSCIENCE EDUCATION INSTITUTE (NEI) 2017 CONGRESS
Advertisement
Highlights from the Neuroscience Education Institute (NEI) 2017 Congress, which took place on November 8-12 in Colorado Springs, CO, are available in this newsletter published by The American Journal of Managed Care.
Advertisement
Related to this article
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
3
FDA Approves First Symptomatic Dermographism Treatment
4
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
5